Status:
UNKNOWN
D-dimer to Improve Anticoagulation Outcome During ECMO loNg-term supporteD
Lead Sponsor:
Wuhan Asia Heart Hospital
Conditions:
Extracorporeal Membrane Oxygenation Complication
Thrombosis
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
This was a prospective, cohort study.
Detailed Description
Adult Patients receiving ECMO surpport in Wuhan Asia Heart Hospital were enrolled by cohort. Unfractionated heparin was used for Anticoagulation therapy, APTT or Anti-Xa activity is monitored for dose...
Eligibility Criteria
Inclusion
- Adult Patients
- Receiving ECMO surpport for any reason
Exclusion
- The duration of ECMO surpport was less than 24 hours .
- Those who had difficulty in compliance or were unavailable for follow-up.
Key Trial Info
Start Date :
March 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 30 2023
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT03261284
Start Date
March 1 2019
End Date
December 30 2023
Last Update
April 18 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhang litao
Wuhan, Hubei, China, 430022